Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Cisplatin plus paclitaxel chemotherapy with or without bevacizumab in postmenopausal women with previously untreated advanced cervical cancer: a retrospective study ; volume:21 ; number:1 ; day:6 ; month:2 ; year:2021 ; pages:1-8 ; date:12.2021
BMC cancer ; 21, Heft 1 (6.2.2021), 1-8, 12.2021
- Creator
-
Chu, Guanghua
Liu, Xiangzhen
Yu, Weiguang
Chen, Meiji
Dong, Lingyun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-07869-7
- URN
-
urn:nbn:de:101:1-2021032919164458425429
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chu, Guanghua
- Liu, Xiangzhen
- Yu, Weiguang
- Chen, Meiji
- Dong, Lingyun
- SpringerLink (Online service)
Other Objects (12)
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Secondary sclerosing cholangitis after chemotherapy with bevacizumab and paclitaxel
Role of inflammation in previously untreated macular edema with branch retinal vein occlusion
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer
Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy
Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors
Obinutuzumab plus bendamustine in previously untreated patients with CLL: a subgroup analysis of the GREEN study
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial